Quality of life in patients with schizophrenia: A 2-year cohort study in primary mental health care in rural China

Xiao-Yan He1,2, Christine Migliorini3, Zhuo-Hui Huang2, Fei Wang2, Rui Zhou2, Zi-Lang Chen4, Yao-Nan Xiao4, Qian-Wen Wang2, Shi-Bin Wang2, Carol Harvey5 and Cai-Lan Hou2*

1Iwate Worker’s Hospital, Iwate, China, 2Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangdong Mental Health Center, Guangzhou, China, 3Psychosocial Research Centre, Department of Psychiatry, University of Melbourne, Melbourne, VIC, Australia, 4Luoding Mental Health Center, Yunfu, China, 5Peking University Institute of Mental Health, NHSC Key Laboratory of Mental Health, National Clinical Research Center for Mental Disorders (Peking University), National Clinical Research Center for Mental Disorders (Peking University), National Clinical Research Center for Mental Disorders (Peking University), Beijing, China

Objective: Quality of life (QoL) has been always an important way to evaluate the outcomes of schizophrenia, but there have been few previous longitudinal studies and few in middle-income countries. This study aimed to explore the QoL in Chinese patients with schizophrenia treated in primary mental health care and the risk factors of QoL over time.

Methods: Patients with schizophrenia treated in primary mental health care in rural/regional areas in Luoding, Guangdong, PR China, were evaluated with an extended questionnaire including the Chinese version of the World Health Organization Quality of Life (WHOQOL-BREF) at baseline and 2-year follow-up. Bivariate and multivariate analyses were conducted including Generalized Estimated Equation analyses (GEE).

Results: Four hundred and ninety-one patients with schizophrenia in primary care completed the 2-year follow up evaluation. The QoL physical, environmental, and social relationships domains showed improvement after the 2-year period, but the psychological domain did not. GEE results showed that earlier age of onset, older age, being employed, being unmarried, the thicker waist circumference, less use of clozapine or other SGAs, fewer hospitalizations, more frequent insomnia, more severe depressive and negative symptoms as well as worse treatment insight were independently associated with poor QoL in patients with schizophrenia.

Conclusion: According to our results, to improve the quality of life of patients with schizophrenia in primary care, we should pay more attention to the treatment of depression, negative and insomnia symptoms of schizophrenia, the choice and dosage of antipsychotic medication and improvement in the treatment compliance. The combined use of educational and behavioral strategies may improve treatment adherence.

Keywords
schizophrenia, quality of life, primary care, risk factors, China
Introduction

Schizophrenia, one of the most common severe mental diseases, seriously undermines human health and is associated with a heavy socio-economic burden on patients’ families and society (1). Traditionally, schizophrenia research has majorly focused on symptoms, clinical outcomes, morbidity, treatment modalities, and prediction of clinical syndrome recovery (2, 3). However, to provide comprehensive services to patients with schizophrenia and better support their return to community life, studies have increasingly paid attention to their quality of life (QoL).

WHO defines Quality of Life as an individual’s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns (Available from https://www.who.int/tools/whoqol). QoL has become an important outcome for evaluating the treatment outcomes of schizophrenia (4, 5). Boyer et al. reported that QoL is one of the most important features for predicting the recurrence of schizophrenia. The higher the patient’s QoL, the lower the likelihood of relapse within 2 years (6).

Compared to healthy controls or their non-affected siblings, the QoL for patients with schizophrenia has been shown to be markedly reduced (7, 8). A large number of studies, including meta-analyses, have evaluated the QoL and its influential factors in schizophrenic patients (9). Severe positive and negative psychotic symptoms (10), severe depressive symptoms (11, 12), and worse sleeping disturbance patterns (13) are associated with worse quality of life as well as low levels of social functioning. Antipsychotics are extremely important for treatment of schizophrenia. In the past 60 years, various studies have published on the use of antipsychotics for treatment of schizophrenia, with the major research trends being: (1) antipsychotic efficacy; (2) cognition in schizophrenia; (3) side effects of antipsychotics (14), all of which affect the QoL of schizophrenia patients.

However, most of these studies were based on cross-sectional designs. Longitudinal, repeated measures designs using large study samples are better placed to inform on factors that can influence QoL in people with schizophrenia.

Further, most studies were performed in western countries. The QoL is influenced by socio-cultural and economic factors (15, 16). Xiang et al. showed that severe positive symptoms are predictive of low levels of social and environmental domains of QoL in Chinese patients. This finding is contrary to the commonly held belief that QoL is highly associated with negative symptoms and weakly associated or independent of positive symptoms (17).

Compared to developed countries (18, 19), China’s communal mental health system is not well-established. QoL varies between countries and is correlated with national economic growth, spiritual budget, and other factors (20). Therefore, we adopted a 2-year longitudinal design to assess the relative effects of demographic and clinical characteristics to the QoL for patients with schizophrenia in the community and managed in a primary mental health system in a non-western country.

Study participants and methods

Ethical considerations

This study was jointly undertaken by the Guangdong mental health center, Guangdong Province, China, and the University of Melbourne, with ethical approval obtained at both institutions. All participants, as well as their guardians, gave written informed consents.

Study participants

Schizophrenic patients were selected from the China National Psychiatric Management System (CNPMS) through a random cluster sampling method. CNPMS is a Chinese system for registration and management of patients with severe mental illnesses, including schizophrenia, bipolar disorders, paranoid psychosis, schizoaffective disorders, mental disorders related to epilepsy, and intellectual disability with psychotic symptoms. In this study, all patients were from Luoding city, an underdeveloped rural area in Guangdong Province.

The inclusion criteria were: (a) Aged above 18; (b) Have an ICD-10 diagnosis of schizophrenia, not including ultra-high risk for psychosis (UHR), but included first-episode schizophrenia (FEP), as it was not specifically distinguished between patients with first-episode or recurrent schizophrenia; (c) Living in Luoding city and receiving treatment in outpatient clinics or in the community; (d) Able to understand and read questionnaire contents.

First, the sampled schizophrenic patients were contacted by telephone to clarify the details of the research protocol. If they were willing to participate, one of three psychiatrists, each with more than 5 years of clinical experience, conducted a face-to-face interview with patients. After the interview, patients were included in the study if they met the inclusion criteria. A detailed description of baseline characteristics and data collection is provided elsewhere (21). Two years later, we followed up on enrolled individuals. The flowchart for this study is shown in Figure 1.

Assessments

Data on socio-demographic variables (age, gender, marital status, education level, employment status) and clinical
characteristics [number of hospitalizations, first episode or not, age of onset of illness, Body Mass Index (BMI)] were collected at interview. Data on the use of first-generation antipsychotics (FGAs), second-generation antipsychotics (SGAs), antidepressants, mood stabilizers, benzodiazepines, and anticholinergic drugs were obtained from medical records.

Symptomatology was determined using the Chinese version of the Brief Psychiatric Rating Scale (BPRS), which had been tested for reliability and validity (22, 23). The BPRS was used to rate the presence or absence of psychiatric symptoms, and the severity of each symptom; it consists of 18 items and each item is graded from 1 to 7 (where a rating of seven indicates extreme severe). The higher the score, the more severe the symptom.

Depressive symptoms were assessed using the Chinese version of the Montgomery-Åsberg Depression Rating Scale (MADRS), with good reliability and validity (24, 25). The scale has 10 items assessed on a 7-point scale. Typically, a score of <12 indicates no depressive symptoms, with higher scores representing greater depressive symptoms.

Insight was measured using the Chinese version of the Insight and Treatment Attitude Questionnaire (ITAQ), which had been tested for reliability and validity (26, 27). The ITAQ scale includes 11 items (five items: awareness into illness or illness insight, six items: awareness into need for medical/hospitalization treatment or treatment insight). Items are rated on a scale of 0 (no insight) to 2 (good insight), and a higher total score means better insight.

An eight-question self-report scale was used to evaluate the sleep status of participants over the past month (8, 28). The scale included four sub-domains: any type of insomnia [e.g., difficulty initiating sleep (Over the past month, have you had trouble falling asleep), difficulty maintaining sleep (Over the past month, have you had difficulty maintaining sleep for a long time or waking up from time to time?) and early morning wakening (For the past month, have you had trouble waking up in the middle of the night or waking up too early to go to sleep again)]; whether insomnia requires treatment [Have you been using sleeping pills (medicines) for insomnia for the past 1 month?]; whether bothered by insomnia [Have you been bothered by insomnia for the past 1 month?]; whether insomnia affects life, work and study [Have you suffered from insomnia that affects life, work, and study for the past 1 month?].

We used a six-question self-report scale to assess suicide-related problems of participants over the past 2 weeks. The scale has three domains: whether patients had suicidal thoughts, suicidal behaviors or had attempted suicide (29). Suicidality was judged to have occurred in the past 2 weeks if one or more of the three aspects were answered in the affirmative.

Quality of life was measured using the Chinese version of the abridged World Health Organization Quality of Life instrument (WHOQOL-BREF), which had been tested for reliability and validity (30). The WHOQOL-BREF scale consists of 28 items, in which each item is scored on a 5-point Likert-scale that measures four domains: physical health (seven-items), psychological health (six-items), social relationship (three-items), environmental health (eight-items) plus four items. Only the four domain scores were used in analyses. A higher score reflects better quality of life.

Before study implementation, three investigators performed the inter-rater reliability training for 20 schizophrenic patients. Inter-rater reliability training of the tools yielded satisfactory agreement (>0.90).

**Statistical analysis**

The IBM SPSS software version 22.0 and 25.0 was used for analyses. A total of 491 patients completed the follow-up.
Socio-demographic and clinical characteristics of schizophrenic patients who completed the 2 years of follow-up and those who were lost to follow-up were compared using the independent samples t-test and Chi square tests. We analyzed differences in socio-demographic, clinical characteristics, and QoL domains between baseline and follow-up groups using the paired samples t-test and McNemar test. QoL was compared between patients with schizophrenia (at baseline, after 2 years) and the general Chinese population (NORM) using the summary independent samples t-test. In large scale studies, very small effects may reach statistical significance. To determine whether effects have a relevant magnitude, effect sizes are used to describe the strength of a phenomenon. Conventionally, when comparing two mean values, the Cohen d value is calculated as the effect size, where 0.2 represents a small effect size, 0.5 represents a medium effect size, and 0.8 represents a large effect size (31). When comparing dichotomous variables, the phi value is calculated as the effect size, whereby 0.1 represents a small effect size, 0.3 represents a medium effect size, and 0.5 represents a large effect size (32).

Generalized Estimating Equations (GEE) were used to assess the risk factors for QoL domains in the cohort of 491 patients with schizophrenia. GEE is mainly used for analysis of repeated measurement data, such as longitudinal observation of epidemiological populations, where there are more flexible observation time points. For predictor variables, time dependent variables can be included. Therefore, GEE is suitable for statistical analysis in this study. The selection of independent variables in GEE analysis was based on clinical experience, other relevant studies and on positive results. The dependent variable was the follow-up WHOQOL-BREF score. \( p \leq 0.05 \) was the threshold for statistical significance (two-tailed).

Changes in demographic and clinical variables

Bivariate comparison analyses revealed that at follow-up, participants were more likely to be unemployed (medium effect size). The number of medications prescribed increased over the 2-year period, with significant increases noted for all types, except FGAs (Table 2). Over the 2-year period, the BMI markedly increased, as did waist circumference.

While the number of participants having, and receiving treatment for insomnia was relatively stable, fewer participants reported being bothered by insomnia or insomnia affecting their lives. At follow-up, significantly more participants reported having suicide-related thoughts, behaviors or attempts in previous 2 weeks (Table 2).

At 2-year follow up, there were significant increases in depression symptoms (\( p = 0.002, d = 0.137 \)), which affected the symptomatic score (\( p < 0.001, d = 0.178 \)), while there were decreases (i.e., improvements) in BPRS total (\( p = 0.032, d = 0.097 \)) and negative symptom scores (\( p < 0.001, d = 0.181 \)). Although changes in positive symptoms were not significant, there was a trend toward improvement (\( p = 0.062, d = 0.084 \)). In contrast, there was a decrease (i.e., worsening) in ITAQ illness scores (\( p = 0.001, d = 0.148 \)). After 2 years, there was a general improvement in other domains of QoL besides the psychological domain.

Also, the results showed that all four aspects of QoL in schizophrenia patients were poorer at baseline relative to the Chinese general population, and the QoL after 2 years was still poorer than that of the Chinese general population except for the environmental domain, which was higher than that of the Chinese general population (Table 3).

Risk factors of WHOQOL domains (GEE)

Generalized Estimated Equation analyses revealed that early onset age, being employed, reduced use of SGAs other than clozapine, fewer lifetime hospitalizations, frequent insomnia as well as more severe depressive and negative symptoms were independently associated with poor QoL physical domain (Table 4), while early onset age, less use of clozapine, fewer lifetime hospitalizations, thicker waist circumference, more frequent insomnia, as well as more severe depressive and negative symptoms were independently associated with poor QoL psychological domain (Table 5). Moreover, early onset age, being unmarried, older age, less use of SGAs except clozapine, fewer lifetime hospitalizations, more frequent insomnia, more severe depressive and negative symptoms, as well as worse treatment insights were independently associated with poor QoL social relationship domain (Table 6). Early onset age, less use of SGAs except clozapine, fewer
### TABLE 1 Sociodemographic and clinical characteristics of the study sample.

| Completed follow-up sample (n = 491) | Loss to follow-up sample (n = 251) | Statistics | Effect size |
|-------------------------------------|-------------------------------------|------------|-------------|
| **n** | **%** | **n** | **%** | **χ²** | **df** | **p**-Value | **Phi** |
| Male | 313 | 63.74 | 149 | 59.36 | 1.36 | 1 | 0.24 | 0.04 |
| Married | 213 | 43.38 | 115 | 45.82 | 0.40 | 1 | 0.52 | −0.02 |
| Employed | 318 | 64.76 | 170 | 67.73 | 0.65 | 1 | 0.42 | −0.03 |
| Living with others | 453 | 92.26 | 241 | 96.02 | 3.87 | 1 | 0.05 | −0.07 |
| Current drinker | 20 | 4.1 | 8 | 3.2 | 0.3 | 1 | 0.54 | 0.02 |
| First episode | 47 | 9.57 | 33 | 13.15 | 2.21 | 1 | 0.14 | −0.06 |
| Physical disease | 27 | 5.50 | 22 | 8.76 | 2.87 | 1 | 0.09 | 0.06 |
| Family psychiatric history | 111 | 22.61 | 57 | 22.71 | 0.001 | 1 | 0.98 | −0.001 |
| On clozapine | 104 | 21.18 | 31 | 12.35 | 8.70 | 1 | 0.003 | 0.11 |
| On FGAs | 143 | 29.12 | 57 | 22.71 | 3.47 | 1 | 0.06 | 0.07 |
| On SGAs other than clozapine | 226 | 46.03 | 120 | 47.81 | 0.21 | 1 | 0.65 | −0.02 |
| On antidepressant | 8 | 1.63 | 4 | 1.59 | 0.001 | 1 | 0.97 | 0.001 |
| On benzodiazepine | 22 | 4.48 | 11 | 4.38 | 0.004 | 1 | 0.95 | 0.002 |
| On mood stabilizer | 58 | 11.81 | 23 | 9.16 | 1.20 | 1 | 0.27 | 0.04 |
| On anticholinergic | 164 | 33.40 | 81 | 32.27 | 0.09 | 1 | 0.75 | 0.01 |
| Insomnia in past 1 month | 241 | 49.08 | 121 | 48.21 | 0.05 | 1 | 0.82 | 0.01 |
| Insomnia treatment | 71 | 14.46 | 37 | 14.74 | 0.01 | 1 | 0.92 | −0.004 |
| Insomnia bother | 176 | 35.85 | 84 | 34.47 | 0.41 | 1 | 0.52 | 0.02 |
| Insomnia affects life | 167 | 34.01 | 87 | 34.66 | 0.03 | 1 | 0.86 | −0.006 |
| Suicide related issues in past 2 weeks | 5 | 1.02 | 2 | 0.79 | 0.09 | 1 | 0.76 | 0.01 |

| | **Mean** | **SD** | **Mean** | **SD** | **t** | **df** | **p**-Value | **Cohen's d** |
|-----------------|---------|---------|---------|---------|-------|-------|-----------|-------------|
| Age (years)     | 40.35   | 11.91   | 38.86   | 13.42   | 1.48  | 740   | 0.12      | 0.12        |
| Education level (years) | 8.27   | 2.16   | 8.17   | 2.30   | 0.56  | 740   | 0.58      | 0.05        |
| Age of onset (years) | 26.20   | 9.18   | 25.79   | 9.24   | 0.58  | 740   | 0.56      | 0.05        |
| Number of hospitalizations | 2.16   | 1.92   | 1.80   | 1.97   | 2.34  | 740   | 0.02      | 0.16        |
| Waist circumference | 64.25   | 7.89   | 63.88   | 8.36   | 0.76  | 740   | 0.45      | 0.06        |
| BMI (kg/m²)     | 21.73   | 2.48   | 21.71   | 2.56   | 0.22  | 740   | 0.83      | 0           |
| BPRS total      | 25.89   | 8.26   | 26.34   | 8.30   | −0.70 | 740   | 0.48      | −0.06       |
| BPRS positive   | 6.12    | 2.73   | 6.08    | 2.56   | 0.20  | 740   | 0.85      | 0.01        |
| BPRS negative   | 5.54    | 2.77   | 5.50    | 2.91   | 0.20  | 740   | 0.84      | 0.01        |
| BPRS affect     | 5.13    | 1.73   | 5.08    | 1.57   | 0.42  | 740   | 0.67      | −0.10       |
| MADRS total     | 4.69    | 5.70   | 5.29    | 5.97   | −1.34 | 740   | 0.18      | 0.03        |
| ITAQ total      | 9.83    | 7.78   | 9.68    | 7.73   | 0.24  | 740   | 0.81      | 0.03        |
| ITAQ illness    | 3.97    | 3.39   | 3.84    | 3.43   | 0.47  | 740   | 0.63      | 0.03        |
| ITAQ medication | 5.86    | 4.60   | 5.84    | 4.54   | 0.06  | 740   | 0.95      | 0           |
| WHOQOL-BREF physical health | 12.26  | 1.41   | 12.10   | 1.53   | 1.48  | 740   | 0.14      | 0.07        |
| WHOQOL-BREF psychological health | 12.53  | 1.22   | 12.44   | 1.40   | 0.88  | 740   | 0.38      | 0.08        |
| WHOQOL-BREF social relationships | 12.10  | 2.09   | 11.81   | 1.87   | 1.83  | 740   | 0.07      | 0.15        |
| WHOQOL-BREF environment | 11.87  | 1.29   | 11.84   | 1.38   | 0.22  | 740   | 0.82      | 0           |

Bold values: p < 0.05.

aPearson chi-square test.

bIndependent-Samples T-Test.

BMI, Body Mass Index; BPRS, Brief Psychiatric Rating Scale; FGAs, First-generation antipsychotics; ITAQ, Insight and Treatment Attitude Questionnaire; MADRS, Montgomery–Asberg Depression Rating Scale; SGAs, second-generation antipsychotics; SDS, Sheehan Disability Scale; WHOQOL-BREF, The World Health Organization Quality of Life- brief version.
**TABLE 2** Comparison of sociodemographic and clinical characteristics between baseline and 2 year follow-up in 491 patients with schizophrenia.

|                        | Baseline | Follow-up | Statistics | Effect size |
|------------------------|----------|-----------|------------|-------------|
|                        | n | % | n | % | $\chi^2$ | df | p-Value | Phi |
| Married                | 213 | 43.38 | 220 | 44.81 | 0.43 | 1 | 0.510 | 0.657 |
| Employed              | 318 | 64.76 | 190 | 38.69 | 70.13 | 1 | <0.001 | 0.140 |
| Physical violence in past 1 year | 205 | 41.75 | 198 | 40.32 | 0.17 | 1 | 0.677 | 0.129 |
| On FGAs               | 143 | 29.12 | 162 | 32.99 | 3.02 | 1 | 0.081 | 0.494 |
| On clozapine          | 104 | 21.18 | 164 | 33.40 | 29.50 | 1 | <0.001 | 0.454 |
| On SGAs other than clozapine | 153 | 31.16 | 288 | 58.66 | 46.64 | 1 | <0.001 | −0.551 |
| On antidepressant     | 8 | 1.63 | 19 | 3.87 | 13.47 | 1 | <0.001 | 0.482 |
| On benzodiazepine     | 22 | 4.48 | 75 | 15.27 | 34.23 | 1 | <0.001 | 0.154 |
| On mood stabilizer    | 58 | 11.81 | 109 | 22.20 | 22.12 | 1 | <0.001 | 0.214 |
| On anticholinergic    | 164 | 33.40 | 203 | 41.34 | 7.89 | 1 | 0.005 | 0.212 |
| Insomnia in past 1 month | 205 | 41.75 | 198 | 40.32 | 0.17 | 1 | 0.677 | 0.129 |
| Insomnia treatment    | 71 | 14.46 | 81 | 16.50 | 0.66 | 1 | 0.415 | 0.051 |
| Insomnia bother       | 176 | 35.85 | 87 | 17.72 | 42.79 | 1 | <0.001 | 0.109 |
| Insomnia affects life | 167 | 34.01 | 65 | 13.24 | 59.31 | 1 | <0.001 | 0.100 |
| suicide related issues in 2 weeks | 5 | 1.02 | 17 | 3.46 | 6.72 | 1 | 0.008 | 0.203 |

**Table 7**

|                          | Mean | SD | Mean | SD | t^b | df | p-Value | Cohen's $d$ |
|--------------------------|------|----|------|----|-----|----|---------|-------------|
| Number of hospitalizations | 2.16 | 1.92 | 3.06 | 2.58 | −16.23 | 490 | <0.001 | 0.732 |
| Waist circumference      | 64.25 | 7.89 | 88.95 | 11.89 | −38.77 | 471 | <0.001 | 1.784 |
| BMI (kg/m^2)             | 21.73 | 2.48 | 24.21 | 4.13 | −11.27 | 473 | <0.001 | 0.518 |
| BPRS total               | 25.89 | 8.26 | 24.96 | 6.38 | 2.16 | 490 | 0.032 | 0.897 |
| BPRS positive            | 6.12 | 2.73 | 5.85 | 2.39 | 1.87 | 490 | 0.062 | 0.084 |
| BPRS negative            | 5.54 | 2.77 | 5.00 | 2.76 | 4.00 | 490 | <0.001 | 0.181 |
| BPRS affect              | 5.13 | 1.73 | 5.54 | 1.68 | −3.94 | 490 | <0.001 | 0.178 |
| MADRS total              | 4.69 | 5.70 | 5.77 | 6.02 | −3.05 | 490 | 0.002 | 0.137 |
| ITAQ total               | 9.83 | 7.78 | 9.47 | 6.39 | 0.95 | 490 | 0.342 | 0.043 |
| ITAQ illness             | 3.97 | 3.39 | 3.43 | 2.82 | 3.29 | 490 | 0.001 | 0.148 |
| ITAQ medication          | 5.86 | 4.60 | 6.04 | 3.92 | −0.81 | 490 | 0.416 | 0.037 |
| WHOQOL-BREF physical health | 12.26 | 1.41 | 13.92 | 1.73 | −17.60 | 490 | <0.001 | 0.794 |
| WHOQOL-BREF psychological health | 12.53 | 1.22 | 12.57 | 1.98 | −0.43 | 490 | 0.668 | 0.019 |
| WHOQOL-BREF social relationships | 12.10 | 2.09 | 12.78 | 2.38 | −4.88 | 490 | <0.001 | 0.220 |
| WHOQOL-BREF environment | 11.87 | 1.29 | 12.42 | 1.77 | −5.88 | 490 | <0.001 | 0.265 |

Bold values: p < 0.05.
McNemar Test.
Paired-samples T-Test.
BMI, Body Mass Index; BPRS, Brief Psychiatric Rating Scale; FGAs, First-generation antipsychotics; ITAQ, Insight and Treatment Attitude Questionnaire; MADRS, Montgomery–Asberg Depression Rating Scale; SGAs, second-generation antipsychotics; SDS, Sheehan Disability Scale; WHOQOL-BREF, The World Health Organization Quality of Life—brief version.

Discussion

The results showed that all four aspects of QoL in schizophrenia patients were poorer at baseline relative to the general population, but the QOL after 2 years was still poorer than that of the general population except for the environmental aspect. Lifetime hospitalizations, more frequent insomnia, more severe depressive and negative symptoms, as well as worse treatment insights were independently associated with poor QoL environment domain (Table 7). To illustrate these results, a summary table was made regarding the four aspects of QoL (Table 8).
domain, which was higher than that of the general population, probably because the environmental domain mainly examined were living environment, medical insurance, transportation, etc. Probably because of China’s development, these aspects improved relatively quickly.

We found that with exception of the psychological domain, there was a general improvement in QoL. The stability of QoL among adults with schizophrenia has yet to be fully established. Some studies reported insignificant changes in QoL for some patients (33), while others reported marked improvements in QoL. These inconsistent outcomes may be due to differences in follow-up times and assessment methods used (34, 35). For instance, Ritsner et al. used the Quality of Life Enjoyment and Life Satisfaction Questionnaire (Q-LES-Q), whereas Gardsjord et al. used the Lehman’s Quality of Life Interview to measure subjective quality of life. The mean age at baseline for patients in studies by Ritsner et al. and Gardsjord et al. were 38 and 28 years, respectively. In addition, there are differences in health systems among countries (36). These inconsistent findings warrant further investigations using the same measures across different samples for greater comparability. Regardless of the type of antipsychotic drugs used, patients treated in primary mental health care are usually stable or in remission, which may reduce the impacts of psychopathology as well as side effects on QoL.

Generalized Estimated Equation analysis revealed that the risk factors with significant effects on QoL of patients with schizophrenia included onset age, age, working status, marital status, number of lifetime hospitalizations, treatment with SGAs other than clozapine, treatment with clozapine, insomnia, depressive and negative symptoms.

The earlier the onset age, the worse the QoL for patients living with/diagnosed with schizophrenia, consistent with previous studies (37). It may be that patients with early onset age have poorer educational and vocational adjustment (38), and have worse social functioning (39). This result underscores the importance of early rehabilitation so as to reduce subsequent functional impairment and disability.

We also found that older age has a negative impact on psychological and social relationship domains of the QoL of schizophrenia patients. Consistently, a previous study reported that the QoL in older patients with schizophrenia was lower (8). Similarly, a recent study showed that patients aged 55–64 had lower QoL (40). In addition, a meta-analysis revealed that older age was significantly associated with poorer QoL in schizophrenia patients (41). This may be due to poor general health and higher prevalence of somatic co-morbidity in old age (42).

A higher use of clozapine or other second-generation antipsychotics was significantly associated with improved QoL. It has been reported that second-generation antipsychotics, including clozapine, are able to improve both positive and negative symptoms, while symptom reduction can improve the QoL for schizophrenic patients. In this study, the use of clozapine or other second-generation antipsychotics improved significantly after 2 years, with significant improvements in negative symptoms and insignificant reduction in positive symptoms. Therefore, patients may have improved their QoL through this modality (43, 44).

However, previous studies on the impact of second-generation antipsychotics on QoL have not been conclusively determined. Some studies have argued that compared to first-generation antipsychotics, second-generation antipsychotics fail to significantly improve the QoL of schizophrenic patients due to metabolic syndromes and obesity (45, 46), while some studies found that second-generation antipsychotic drugs can significantly improve the QoL for schizophrenic patients (47, 48). These inconsistent findings may be related to various factors, including the rate of using second-generation antipsychotics, study designs, sample sizes, and selected characteristics among others.

Insomnia is a common sleep disorder in schizophrenic patients (49). In this study, whether at baseline or after 2 years follow-up, about half of the patients suffered from insomnia, which had a significant negative impact on their QoL, in tandem with findings from previous studies (50, 51). Insomnia affects the patient’s ability to perform daily tasks and participate in social activities, as well as their ability to function in the society and environment (52–54). This replicated finding is clinically

---

**TABLE 3** Comparison of QoL between schizophrenia patients (at baseline, after 2 years) and the general Chinese population.

|                      | Mean   | SD    | Mean   | SD    | Mean   | SD    | t     | p-Value | t     | p-Value |
|----------------------|--------|-------|--------|-------|--------|-------|-------|---------|-------|---------|
| WHOQOL-BREF physical health | 12.21  | 1.46  | 13.92  | 1.73  | 15.10  | 2.30  | 29.08 | <0.001  | 9.76  | <0.001  |
| WHOQOL-BREF psychological health | 12.50  | 1.28  | 12.57  | 1.98  | 13.89  | 1.89  | 16.71 | <0.001  | 11.89 | <0.001  |
| WHOQOL-BREF social relationships | 12.00  | 2.02  | 12.78  | 2.38  | 13.93  | 2.06  | 18.43 | <0.001  | 9.11  | <0.001  |
| WHOQOL-BREF environment | 11.86  | 1.32  | 12.42  | 1.77  | 12.14  | 2.08  | 3.12  | 0.002   | 2.56  | 0.01    |

Bold values: p < 0.05.

aSummary independent samples T-Test.

bBaseline (n = 742); cFollow-up (n = 491); dGeneral population pattern in China (n = 777).

WHOQOL-BREF, The World Health Organization Quality of Life- brief version.
TABLE 4 Generalized Estimating Equations (GEE) results modeling risk factors associated with WHQOL physical domain in 491 patients with schizophrenia.

| Baseline variables | Coef  | SE   | p-Values | OR   | 95% CI(OR) |
|--------------------|-------|------|----------|------|------------|
| Male               | 0.06  | 0.12 | 0.63     | 1.06 | 0.82–1.36  |
| Living with others | 0.15  | 0.18 | 0.41     | 1.16 | 0.808–1.67 |
| First episode      | −0.04 | 0.17 | 0.809    | 0.95 | 0.68–1.34  |
| Current drinker    | −0.07 | 0.24 | 0.77     | 0.93 | 0.57–1.51  |
| Current smoker     | 0.15  | 0.11 | 0.19     | 1.16 | 0.92–1.47  |
| Physical disease   | 0.04  | 0.22 | 0.85     | 1.04 | 0.66–1.62  |
| Family psychiatric history | −0.109 | 0.12 | 0.37     | 0.89 | 0.703–1.14 |
| Physical violence in past 1 year | −0.17 | 0.109 | 0.11 | 0.84 | 0.67–1.04 |
| Education level (years) | 0.01 | 0.02 | 0.58     | 1.01 | 0.96–1.06  |
| Age of onset (years) | 0.01 | 0.008 | 0.04 | 1.01 | 1.00–1.03  |

| Time-dependent variables | Coef  | SE   | p-Values | OR   | 95% CI(OR) |
|--------------------------|-------|------|----------|------|------------|
| Married                  | 0.03  | 0.13 | 0.77     | 1.03 | 0.801–1.34 |
| Employed                 | −0.39 | 0.109| <0.001   | 0.67 | 0.54–0.83  |
| On FGAs                  | 0.02  | 0.12 | 0.82     | 1.02 | 0.805–1.31 |
| On Clozapine             | 0.19  | 0.12 | 0.105    | 1.21 | 0.96–1.53  |
| On SGAs other than clozapine | 0.38 | 0.11 | 0.001    | 1.46 | 1.15–1.84  |
| On antidepressant        | −0.48 | 0.35 | 0.16     | 0.61 | 0.308–1.22 |
| On benzodiazepine        | 0.24  | 0.21 | 0.24     | 1.27 | 0.84–1.92  |
| On mood stabilizer       | −0.12 | 0.14 | 0.37     | 0.88 | 0.66–1.16  |
| On Anticholinergic       | −0.15 | 0.11 | 0.18     | 0.85 | 0.67–1.07  |
| insomnia in past 1 month | −0.49 | 0.108| <0.001   | 0.61 | 0.49–0.75  |
| Suicide related issues in 2 weeks | 0.51 | 0.37 | 0.16     | 1.66 | 0.804–3.46 |
| Age (years)              | −0.002| 0.006| 0.72     | 0.99 | 0.98–1.01  |
| Number of hospitalizations | 0.07 | 0.02 | 0.01     | 1.07 | 1.01–1.13  |
| Waist circumference      | <0.001| <0.001| 0.73     | 1.00 | 0.99–1.002 |
| BMI (kg/m²)              | <0.001| <0.001| 0.73     | 1.00 | 0.99–1.002 |
| BPRS positive            | 0.009 | 0.03 | 0.78     | 1.009| 0.94–1.07  |
| BPRS negative            | −0.12 | 0.02 | <0.001   | 0.88 | 0.83–0.92  |
| BPRS affect              | −0.03 | 0.03 | 0.29     | 0.96 | 0.89–1.03  |
| MADRS total              | −0.03 | 0.01 | 0.002    | 0.96 | 0.94–0.98  |
| ITAQ illness             | −0.05 | 0.03 | 0.11     | 0.95 | 0.89–1.01  |
| ITAQ medication          | 0.03  | 0.02 | 0.18     | 1.03 | 0.98–1.08  |

Bold values: p < 0.05.

a The value of baseline variables would not change during the whole follow-up period.
b The value of time-dependent variables would change during follow-up period.

BPRS, Brief Psychiatric Rating Scale; FGAs, First-generation antipsychotics; ITAQ, Insight and Treatment Attitude Questionnaire; MADRS, Montgomery–Asberg Depression Rating Scale; SGAs, second-generation antipsychotics.

significant, because it points to a window for maintaining the QoL as it provides a basis for clinicians to establish interventions for schizophrenia. Efforts should aim at improving patients’ sleep problems using medications or cognitive behavioral therapy, thereby improving patients’ QoL (55).

Negative symptoms were also shown to have a negative effect on QoL, consistent with previous studies (56–58). In their meta-analysis, Design et al. showed that culturally-adapted psychosocial interventions for schizophrenia can reduce negative symptoms (59). Therefore, targeting social skills and increasing daily activities for patients with high negative symptoms may be effective for improving the QoL for schizophrenic patients. In addition, physical exercise also had a beneficial for negative symptoms (60).

Depressive symptoms were significantly and negatively associated with each of the QoL domains. This finding is similar to those of previous studies and points to the sweeping deleterious effect of persistent depressive symptoms on QoL of patients with schizophrenia (12, 34). Therefore, the need for active treatment of depression in
TABLE 5 Generalized Estimating Equations (GEE) results modeling risk factors associated with WHOQOL psychological domain in 491 patients with schizophrenia.

| Baseline variables<sup>a</sup> | Coef  | SE   | p-Value | OR   | 95% CI (OR) |
|-------------------------------|-------|------|---------|------|-------------|
| Male                          | 0.17  | 0.11 | 0.12    | 1.19 | 0.95–1.48   |
| Living with others            | -0.06 | 0.17 | 0.702   | 0.93 | 0.66–1.31   |
| First episode                 | 0.22  | 0.16 | 0.15    | 1.25 | 0.91–1.72   |
| Current drinker               | -0.12 | 0.24 | 0.607   | 0.88 | 0.54–1.43   |
| Current smoker                | 0.06  | 0.11 | 0.59    | 1.06 | 0.84–1.34   |
| Physical disease              | -0.303| 0.21 | 0.15    | 0.73 | 0.48–1.11   |
| Family psychiatric history    | -0.007| 0.11 | 0.95    | 0.99 | 0.79–1.24   |
| Physical violence in past 1 year| -0.17 | 0.10 | 0.08    | 0.84 | 0.69–1.02   |
| Education level (years)       | 0.03  | 0.02 | 0.14    | 1.03 | 0.98–1.08   |
| Age of onset (years)          | 0.03  | 0.007| <0.001  | 0.01 | 1.02–1.04   |

| Time-dependent variables<sup>b</sup> | Coef  | SE   | p-Value | OR   | 95% CI (OR) |
|-------------------------------------|-------|------|---------|------|-------------|
| Married                             | -0.16 | 0.11 | 0.17    | 0.85 | 0.67–1.07   |
| Employed                            | 0.17  | 0.09 | 0.08    | 1.18 | 0.97–1.44   |
| On FGAs                             | -0.07 | 0.105| 0.508   | 0.93 | 0.75–1.14   |
| On clozapine                        | 0.29  | 0.12 | 0.01    | 1.33 | 1.05–1.69   |
| On SGAs other than clozapine        | 0.17  | 0.102| 0.08    | 1.19 | 0.97–1.45   |
| On antidepressant                   | -0.11 | 0.29 | 0.69    | 0.88 | 0.49–1.59   |
| On benzodiazepine                   | -0.01 | 0.17 | 0.91    | 0.98 | 0.69–1.38   |
| On mood stabilizer                  | -0.07 | 0.14 | 0.61    | 0.93 | 0.705–1.22  |
| On anticholinergic                  | -0.17 | 0.108| 0.106   | 0.84 | 0.67–1.03   |
| Insnomia in past 1 month            | -0.33 | 0.09 | 0.001   | 0.71 | 0.58–0.86   |
| Suicide related issues in past 2 weeks| -0.21 | 0.43 | 0.62    | 0.81 | 0.34–1.88   |
| Age (years)                         | -0.01 | 0.005| 0.01    | 0.98 | 0.97–0.99   |
| Number of hospitalizations          | 0.08  | 0.02 | <0.001  | 1.09 | 1.04–1.14   |
| Waist circumference                 | 0.002 | <0.001| 0.04    | 0.99 | 0.99–1.00   |
| BMI (kg/m<sup>2</sup>)              | 0.001 | <0.001| 0.13    | 1.001| 1.00–1.003  |
| BPRS positive                       | 0.04  | 0.02 | 0.08    | 1.04 | 0.99–1.103  |
| BPRS negative                       | -0.07 | 0.02 | 0.002   | 0.92 | 0.88–0.97   |
| BPRS affect                         | -0.01 | 0.03 | 0.72    | 0.98 | 0.92–1.05   |
| MADRS total                         | -0.06 | 0.01 | <0.001  | 0.94 | 0.92–0.96   |
| ITAQ Illness                        | -0.02 | 0.02 | 0.43    | 0.97 | 0.92–1.03   |
| ITAQ Medication                     | 0.05  | 0.02 | 0.02    | 1.05 | 1.005–1.10  |

Bold values: p < 0.05.<sup>a</sup>The value of baseline variables would not change during the whole follow-up period.<sup>b</sup>The value of time-dependent variables would change during follow-up period.

BPRS, Brief Psychiatric Rating Scale; FGAs, First-generation antipsychotics; ITAQ, Insight and Treatment Attitude Questionnaire; MADRS, Montgomery–Asberg Depression Rating Scale; SGAs, second-generation antipsychotics.

the full course of treatment of schizophrenia has been reaffirmed (61). Our study also showed that a better treatment insight rather than illness insight may have a positive impact on both the social relationship and environmental domains of the QoL in patients with schizophrenia (62). Previous studies have shown that the relationship between insight and QoL is related to the different dimensions of insight. Poor insight predicts poorer therapeutic alliance and treatment adherence (63). In China, there are only about 20,000 registered psychiatrists in China serving 1.4 billion people (64). Because of insufficient psychiatric resources, most patients with stable schizophrenia are treated in primary medical institutions. Thus, treatment adherence is particularly important. Increasing the insight into treatment can help patients understand the necessity of following certain treatment methods to recover and the importance of treatment. In addition, careful attention to treatment adjustments over time is warranted, as well as psychosocial interventions, which can improve QoL and combat depression. Studies have shown that antipsychotic treatment can increases patient insight (65).
TABLE 6 Generalized Estimating Equations (GEE) results modeling risk factors associated with WHQOL Social Relationship domain in 491 patients with schizophrenia.

| Baseline variables<sup>a</sup> | Coef | SE  | p-Value | OR  | 95%CI (OR) |
|-------------------------------|------|-----|---------|-----|------------|
| Male                          | 0.01 | 0.16| 0.93    | 1.01| 0.73−1.39  |
| Living with others            | 0.16 | 0.26| 0.53    | 1.18| 0.70−1.99  |
| First episode                 | −0.15| 0.23| 0.51    | 0.85| 0.54−1.35  |
| Current drinker               | −0.17| 0.36| 0.62    | 0.83| 0.40−1.72  |
| Current smoker                | −0.04| 0.17| 0.82    | 0.96| 0.67−1.36  |
| Physical disease              | 0.02 | 0.29| 0.93    | 1.02| 0.57−1.82  |
| Family psychiatric history    | 0.01 | 0.15| 0.903   | 1.02| 0.74−1.39  |
| Physical violence in past 1 year | −0.03 | 0.14| 0.803   | 0.96| 0.72−1.28  |
| Education level (years)       | 0.04 | 0.03| 0.12    | 1.04| 0.98−1.11  |
| Age of onset (years)          | 0.03 | 0.01| <0.001  | 1.03| 1.01−1.06  |
| Time-dependent variables<sup>b</sup> |   |     |         |     |            |
| Married                       | 0.63 | 0.17| <0.001  | 1.88| 1.35−2.63  |
| Employed                      | −0.104| 0.13| 0.05    | 0.901| 0.68−1.18 |
| On FGAs                       | −0.20 | 0.16| 0.21    | 0.81| 0.59−1.12 |
| On clozapine                  | −0.14| 0.15| 0.34    | 0.86| 0.64−1.16 |
| On SGAs other than clozapine  | 0.33 | 0.15| 0.03    | 1.39| 1.02−1.88 |
| On antidepressant             | −0.28| 0.36| 0.44    | 0.75| 0.36−1.54 |
| On benzodiazepine             | 0.23 | 0.25| 0.36    | 1.25| 0.76−2.06 |
| On mood stabilizer            | −0.23| 0.18| 0.201   | 0.79| 0.55−1.13 |
| On anticholinergic            | −0.204| 0.15| 0.19    | 0.81| 0.60−1.11 |
| Insomnia in past 1 month      | −0.49| 0.14| <0.001  | 0.607| 0.45−0.803|
| Suicide related issues in past 2 weeks | −0.21 | 0.49| 0.65    | 0.805| 0.307−2.11|
| Age (years)                   | −0.03| 0.088| <0.001 | 0.97| 0.95−0.98 |
| Number of hospitalizations    | 0.07 | 0.03| <0.001  | 1.07| 1.01−1.14 |
| Waist circumference           | −0.001| <0.001| 0.19    | 0.99| 0.99−1.001|
| BMI (kg/m<sup>2</sup>)        | 0.001| 0.001| 0.407   | 1.001| 0.99−1.003|
| BPRS positive                 | −0.008| 0.03| 0.82    | 0.99| 0.92−1.06 |
| BPRS negative                 | −0.14| 0.03| <0.001  | 0.86| 0.81−0.92 |
| BPRS affect                   | −0.07| 0.04| 0.14    | 0.93| 0.84−1.02 |
| MADRS total                   | −0.03| 0.01| <0.001  | 0.96| 0.93−0.99 |
| ITAQ illness                  | −0.07| 0.03| 0.07    | 0.93| 0.86−1.007|
| ITAQ medication               | 0.07 | 0.02| 0.01    | 1.07| 1.01−1.13 |

Bold values: p < 0.05.
<sup>a</sup>The value of baseline variables would not change during the whole follow-up period.
<sup>b</sup>The value of time-dependent variables would change during follow-up period.

BPRS, Brief Psychiatric Rating Scale; FGAs, first-generation antipsychotics; ITAQ, Insight and Treatment Attitude Questionnaire; MADRS, Montgomery–Asberg Depression Rating Scale; SGAs, second-generation antipsychotics.

Unlike previous studies (66–68), this study found that participants hospitalized more often reported better QoL. This may be because the sample used in this study was selected from outpatients or community-based patients in rural areas, and the number of admissions was more indicative of regular care. More communication with physicians and higher adherence may lead to higher QoL.

The impact of marital and working status on QoL suggested the importance of psychosocial and environmental factors for patients with schizophrenia. Our findings showed that being employed had a negative impact on the physical domain of QoL. This result was indeed a little surprising, but may be linked to the observation that only a third of participants were employed after about 2 years. The physical domain was mainly the evaluation of participants’ functional-ability. At work, the cognitive decline that participants' experience due to their illness will likely affect their ability to work, increasing the possibility of becoming dissatisfied with themselves, affecting satisfaction in the physical domain. Meanwhile, a previous meta-analysis showed that the causal direction of this association in terms of employment and quality of life remains unclear because studies on the bidirectional relationship between employment
TABLE 7 Generalized Estimating Equations (GEE) results modeling risk factors associated with WHOQOL environment domain in 491 patients with schizophrenia.

| Baseline variables          | Coef  | SE   | p-Value | OR   | 95%CI(OR) |
|-----------------------------|-------|------|---------|------|-----------|
| Male                        | 0.07  | 0.11 | 0.49    | 1.08 | 0.86–1.35 |
| Living with others          | 0.22  | 0.17 | 0.19    | 1.25 | 0.89–1.75 |
| First episode               | 0.07  | 0.16 | 0.62    | 1.08 | 0.79–1.48 |
| Current drinker             | −0.45 | 0.28 | 0.102   | 0.63 | 0.36–1.09 |
| Current smoker              | 0.009 | 0.11 | 0.93    | 1.009| 0.809–1.25|
| Physical disease            | −0.25 | 0.202| 0.21    | 0.77 | 0.52–1.15 |
| Family psychiatric history  | 0.09  | 0.11 | 0.41    | 1.09 | 0.87–1.37 |
| Physical violence in past 1 year | −0.16 | 0.102| 0.11    | 0.85 | 0.69–1.04 |
| Education level (years)     | 0.04  | 0.02 | 0.06    | 1.04 | 0.99–1.08 |
| Age of onset (years)        | 0.02  | 0.007| **0.003**| 1.02 | 1.007–1.03|

| Time-dependent variables    | Coef  | SE   | p-Value | OR   | 95%CI(OR) |
|-----------------------------|-------|------|---------|------|-----------|
| Married                     | 0.07  | 0.11 | 0.48    | 1.08 | 0.86–1.34 |
| Employed                    | −0.17 | 0.09 | 0.07    | 0.84 | 0.69–1.01 |
| On FGAs                     | −0.01 | 0.101| 0.87    | 0.98 | 0.807–1.20|
| On clozapine                | 0.28  | 0.11 | **0.01**| 1.32 | 1.06–1.64 |
| On SGAs other than clozapine| 0.24  | 0.102| **0.01**| 1.27 | 1.04–1.56 |
| On antidepressant           | −0.201| 0.28 | 0.48    | 0.81 | 0.46–1.44 |
| On benzodiazepine           | −0.03 | 0.18 | 0.85    | 0.96 | 0.67–1.38 |
| On mood stabilizer          | −0.17 | 0.13 | 0.21    | 0.84 | 0.64–1.105|
| On Anticholinergic          | −0.04 | 0.09 | 0.69    | 0.96 | 0.79–1.16 |
| Insomnia in past 1 month    | −0.33 | 0.09 | **0.001**| 0.71 | 0.58–0.87 |
| Suicide related issues in past 2 weeks | −0.05 | 0.38 | 0.88    | 0.94 | 0.44–2.01 |
| Age (years)                 | −0.001| 0.005| 0.85    | 0.99 | 0.98–1.009|
| Number of hospitalizations  | 0.05  | 0.02 | **0.009**| 1.05 | 1.01–1.107|
| Waist circumference         | <0.001| <0.001| 0.84    | 1.00 | 0.99–1.002|
| BMI (kg/m²)                 | <0.001| <0.001| 0.89    | 1.00 | 0.99–1.002|
| BPRS positive               | −0.02 | 0.02 | 0.39    | 0.98 | 0.93–1.02 |
| BPRS negative               | −0.08 | 0.02 | **0.001**| 0.92 | 0.87–0.96 |
| BPRS affect                 | 0.006 | 0.03 | 0.85    | 1.006| 0.94–1.07 |
| MADRS total                 | −0.03 | 0.01 | **0.007**| 0.97 | 0.95–0.99 |
| ITAQ illness                | −0.04 | 0.02 | 0.11    | 0.95 | 0.89–1.01 |
| ITAQ medication             | 0.05  | 0.02 | **0.01**| 1.05 | 1.01–1.10 |

Bold values: p < 0.05.

aThe value of baseline variables would not change during the whole follow-up period.
bThe value of time-dependent variables would change during follow-up period.

BPRS, Brief Psychiatric Rating Scale; FGAs, First-generation antipsychotics; ITAQ, Insight and Treatment Attitude Questionnaire; MADRS, Montgomery–Asberg Depression Rating Scale; SGAs, second-generation antipsychotics.

and QoL are lacking (69). Therefore, it will be necessary to further explore the relationship between employment and QoL of patients with schizophrenia in the future (70–72). In this study, married participants experienced better QoL, which is consistent with the studies regarding the impact of marital status on QoL of patients with schizophrenia. In these studies, low QoL was associated with having no reliable friend or daily contact with family members, and having few leisure activities.

The present study has some study limitations. First, many factors that affect QoL, such as self-esteem and stigma, were not assessed. Second, because of a relatively low response rate at 2 years (66%), the results of this study may be more applicable to patients with stronger treatment compliance and cooperation. Third, the population of the study included patients with stable conditions treated in the community or outpatient clinics, excluding inpatients and patients in the acute phase, which could also affect the generalizability of the results. Fourth, the BPRS is not a good scale for assessing negative symptoms, especially defining the threshold for severe negative symptoms. In contrast, the PANSS scale, in relative terms, contains many
more items than the BPRS for clearly defining and measuring negative symptoms (73). Therefore, future studies may need to consider using more precise scales to measure patient symptoms. Fifth, negative symptoms are divided into primary and secondary. Secondary negative symptoms can be caused by positive symptoms, depressive symptoms, and medication side-effects social deprivation substance abuse (74). However, this study did not differentiate between primary negative symptoms or secondary negative symptoms, which need to be considered in future studies. Finally, the patients enrolled in this study were 19–75 years old, spanned a large area, and did not distinguish whether the patients were first-episode or recurrent. Therefore, there is a certain impact on the generalization of the results, and future studies are warranted to further differentiate between patients with age at first presentation and recurrence.

This study has some notable strengths, including a longitudinal design and use of a large data set of standardized and validated measures to evaluate QoL in patients treated in primary mental health care within an emerging economic power - China. This study considered many factors that affect the QoL such as depression, sleep, insight, medication, and attitudes, and observed dynamically the overall QoL in patients with schizophrenia and possible influencing factors. A further strength was the statistical methodology (GEE analysis) used, which is especially suitable for repeated measures data.

Conclusions

This study showed that QoL generally improved over the years in all domains, except the psychological QoL domain. More patients were unemployed after 2 years, used more psychotropic drugs, had more depressive symptoms, fewer negative symptoms (probably fewer secondary negative symptoms), and had worse knowledge of their illness. Further analysis found that to improve the quality of life of patients with schizophrenia in primary care, we should prioritize treatment of depressive, negative and insomnia symptoms, the choice of antipsychotic medication and improvement of the treatment compliance. But, how to operate remains a therapeutic challenge for clinicians, patients, and families because guidelines are unavailable and therapeutic interventions are poorly evaluated. More attention should probably be paid to patients with early onset of illness, older age, and unmarried patients to improve QoL.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Public Health Ethics Committee of Guangdong Provincial People’s Hospital. The patients/participants provided their written informed consent to participate in this study.
Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Funding

This work was supported by Guangdong Provincial Foundation for Basic and Applied Basic Research Natural Science Foundation [grant number: 2022A1515010619]. This study was supported by Guangdong Provincial Innovation Platform of Translational Medicine (Early recognition and intervention of major mental diseases), and Guangdong Provincial Innovation Platform of Public Health.

References

1. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancer Psychiat. (2019) 6:211–24. doi: 10.1016/S2215-0366(18)30511-X

2. Jaakelainen E, Juola P, Hirvonen N, McGrath J, Saha S, Iosihanni M, et al. A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull. (2012) 39:1296–306. doi: 10.1093/schbul/sbx130

3. Woods BT, Ward KE, Johnson EH. Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment. Schizophr Res. (2005) 73:221–8. doi: 10.1016/j.schres.2004.05.014

4. Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia: an update. Pharmacoeconomics. (2012) 30:183–95. doi: 10.2165/11594470-000000000-00000

5. Hofer A, Mizuno Y, Warteletsteiner E, Wolfgang Fleischhacker W, Frajo-Aper B, Kemmler G, et al. Quality of life in schizophrenia and bipolar disorder: the impact of symptomatic remission and resilience. Eur Psychiatry. (2017) 46:42–7. doi: 10.1016/j.eurpsy.2017.08.005

6. Boyer L, Müller A, Perhtame E, Allabba S, Auquier P, Toumi M. Quality of life is predictive of relapse in schizophrenia. BMC Psychiat. (2013) 13:1–8. doi: 10.1186/1471-244X-13-15

7. Law CW, Chen EY, Cheung EF, Chan RC, Wong JG, Lam CL, et al. Impact of untreated psychosis on quality of life in patients with first-episode schizophrenia. Qual Life Res. (2005). 14:1871–81. doi: 10.1007/s11136-005-3236-6

8. Li Y, Hou C-L, Ma X-R, Zhong B-L, Zang Y, Jia F-J. Quality of life in Chinese patients with schizophrenia treated in primary care. Psychiatry Res. (2017) 254:80–4. doi: 10.1016/j.psychres.2017.04.049

9. Watson P, Zhang J-P, Kuriu A, Tamaier J, Birnbaum ML, Kane J. A meta-analysis of factors associated with quality of life in first episode psychosis. Schizophr Res. (2018) 202:226–36. doi: 10.1016/j.schres.2018.07.013

10. Priebe S, McCabe R, Junghan U, Kallert T, Ruggeri M, Slade M, et al. Association between symptoms and quality of life with schizophrenia: a pooled analysis of changes over time. Schizophr Res. (2011) 133:17–21. doi: 10.1016/j.schres.2011.09.021

11. Hou C-L, Ma X-R, Cai M-Y, Li Y, Zang Y, Jia F-J, et al. Comorbidity of moderate–severe depressive symptoms and their association with quality of life in Chinese patients with schizophrenia treated in primary care. Community Ment Health J. (2016) 52:921–6. doi: 10.1007/s10597-016-0523-5

12. van Rooijen M, van Rooijen G, Maat A, Vermeulen JM, Meijer CJ, Ruhé H, et al. Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. Schizophr Res. (2019) 208:82–9. doi: 10.1016/j.schres.2019.04.011

13. Wang W-L, Zhou Y-Q, Chai N-N, Li G-H. Sleep disturbances and quality of life in clinically stable inpatients with schizophrenia in rural China. Qual Life Res. (2020) 29:2759–68. doi: 10.1007/s11136-020-02541-2

14. Sabe M, Pillinger T, Kaiser S, Chen C, Taipale H, Tanskanen A, et al. Half a century of research on antipsychotics and schizophrenia: a scientometric study of hotspots, nodes, bursts, and trends. Neurosci Biobehav Rev. (2022) 136:104608. doi: 10.1016/j.neubiorev.2022.104608

15. Pinakahanah J, Happep B, Hope J, Keks NA. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Ment Health Nurs. (2002) 11:103–11. doi: 10.1044/1446-0979.2002.00233.x

16. Xiang Y-T, Wang C-Y, Wang Y, Chiu HFK, Zhao J-P, Chen Q, et al. Socio-demographic and clinical determinants of quality of life in Chinese patients with schizophrenia: a prospective study. Qual Life Res. (2010) 19:317–22. doi: 10.1007/s11136-010-9593-9

17. Xiang Y-T, Weng Y-Z, Leung C-M, Tang W-K, Ungvari GS. Subjective quality of life in outpatients with schizophrenia in Hong Kong and Beijing: relationship to socio-demographic and clinical factors. Qual Life Res. (2008) 17:27–36. doi: 10.1007/s11136-007-9285-2

18. Osborn LA, Stein CH. Community mental health care providers’ understanding of recovery principles and accounts of directiveness with consumers. Psychiatr Q. (2017) 88:755–67. doi: 10.1007/s11136-017-9495-x

19. Wright WA, Gorman JM, Ondorzyński M, Peterson MJ, Clayton C. Integrated pharmacies at community mental health centers: medication adherence and outcomes. J Manag Care Spec Pharm. (2016) 22:1330–6. doi: 10.18553/jmcp.2016.16004

20. Caqueo-Urizar A, Urriza A, de Munter K, Viveros MJ, Boyer L. Differences on quality of life of patients with schizophrenia: a multicentric study from three latin-america countries. Cult Med Psychiatry. (2019) 43:326–35. doi: 10.1017/10.013-9164-3

21. Huang Y-H, Hou C-L, Ng CH, Chen X, Wang Q-W, Zhang H-Z, et al. Sexual dysfunction in Chinese rural patients with schizophrenia. BMC Psychiatry. (2019) 19:218. doi: 10.1186/s12888-019-2203-5

22. Zhang M, Zhou T, Tang Y, Chi Y, Xia M, Wang Z. The application of translated brief Psychiatric Rating Scale (BPRS) (1) reliability test. Chin J Nerv Ment Dis. (1983) 9:76–80.

23. Zhang M, Zhou T, Liang J, Wang Z, Tang Y, Chi Y, et al. The application of translated brief Psychiatric Rating scale (BPRS) (2) validity test. Chin J Nerv Ment Dis. (1984) 10:74–7.

24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. (1979) 134:382–9. doi: 10.1192/bjp.134.4.382

25. Liu H, Zhang H, Xiao W, Liu Q, Fu P, Chen J, et al. Scales for evaluating depressive symptoms in Chinese patients with schizophrenia. J Nerv Ment Dis. (2009) 197:140–2. doi: 10.1097/NMD.0b013e31819636a5

26. McGorry P, Aland JR, Wilson WH, Gurr W, Hawkins L. Measuring chronic schizophrenia patients’ attitudes toward their illness and treatment. Psychiatr Serv. (1981) 32:856–8. doi: 10.1176/ps.32.12.856

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
69. Ajnakina O, Stubbs B, Francis E, Gaughran F, David AS, Murray RM, et al. Employment and relationship outcomes in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies. *Schizophr Res.* (2021) 231:122–33. doi: 10.1016/j.schres.2021.03.013

70. Woon PS, Chia MY, Chan WY, Sim K. Neurocognitive, clinical and functional correlates of subjective quality of life in Asian outpatients with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* (2010) 34:463–8. doi: 10.1016/j.pnpbp.2010.01.014

71. Bechdolf A, Klosterkötter J, Hambrecht M, Knost B, Kuntermann C, Schiller S, et al. Determinants of subjective quality of life in post acute patients with schizophrenia. *Eur Arch Psychiatry Clin Neurosci.* (2003) 253:228–35. doi: 10.1007/s00406-003-0436-3

72. Thornicroft G, Tansella M, Becker T, Knapp M, Leese M, Schene A, et al. The personal impact of schizophrenia in Europe. *Schizophr Res.* (2004) 69:125–32. doi: 10.1016/S0920-9964(03)00191-9

73. Shafer A, Dazzi F. Meta-analysis of the positive and Negative Syndrome Scale (PANSS) factor structure. *J Psychiatr Res.* (2019) 115:113–20. doi: 10.1016/j.jpsychires.2019.05.008

74. Kirchner M, Aleman A, Kaiser S. Secondary negative symptoms - a review of mechanisms, assessment and treatment. *Schizophr Res.* (2017) 186:29–38. doi: 10.1016/j.schres.2016.05.003